Sign up to save your podcasts
Or
Share NEJM Interview: Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM Interview: Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States.
Dr. James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.C. Robinson. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform. N Engl J Med 2021;385:2017-2019.
View all episodes
By NEJM Group
4.4
120120 ratings
Dr. James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.C. Robinson. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform. N Engl J Med 2021;385:2017-2019.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
135 Listeners
NEJM This Week
318 Listeners
JAMA Clinical Reviews
494 Listeners
JACC This Week
170 Listeners
Clinical Conversations
56 Listeners
Mayo Clinic Talks
290 Listeners
BMJ Best Practice Podcast
22 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
138 Listeners
Core IM | Internal Medicine Podcast
1,151 Listeners
Curbside Consults
90 Listeners
Leadership Conversations
5 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
87 Listeners
The Clinical Problem Solvers
511 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Cardionerds: A Cardiology Podcast
430 Listeners
The Curious Clinicians
369 Listeners
NEJM AI Grand Rounds
57 Listeners
Intention to Treat
32 Listeners
Not Otherwise Specified
58 Listeners